Business Context and Reporting Period
Company: Precision Optics Corporation, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2011
Business Overview: The Company designs and manufactures advanced optical instruments, including medical endoscopes (laparoscopes, arthroscopes), micro-optics, and optical system design services. It operates as a smaller reporting company with facilities in Gardner, Massachusetts, and a subsidiary in Hong Kong.
Key Financial Metrics
| Metric | Fiscal 2011 | Fiscal 2010 |
|---|---|---|
| Revenues | $2,245,137 | $3,094,437 |
| Gross Profit | $752,116 | $1,297,238 |
| Gross Margin | 33.5% | 41.9% |
| Net Loss | $(1,052,613) | $(660,882) |
| Operating Cash Flow | $(413,525) | $52,283 |
| Cash and Equivalents (End of Period) | $19,556 | $416,040 |
| Total Current Liabilities | $2,317,447 | $2,092,948 |
| Senior Secured Convertible Notes | $780,833 | $720,833 |
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased by 27.4% ($849,300) primarily due to lower unit volume sales of endoscopes and an advanced surgical visualization system, alongside a reduction in average product prices. Management attributed this to a lack of capital and the diversion of management time to resolve debt obligations.
- Margin Compression: Gross profit margin fell from 41.9% to 33.5% due to lower sales volume, partially offset by reduced provisions for obsolete inventory.
- Expense Fluctuations: Research and Development (R&D) expenses increased by 55.8% to $825,033, driven by a decrease in customer reimbursements. Selling, General, and Administrative (SG&A) expenses decreased by 19.6% to $958,509 due to reduced executive compensation and consulting fees.
- Liquidity Deterioration: Cash and cash equivalents dropped significantly from $416,040 to $19,556. The Company incurred a net loss of $1.05 million and used $413,525 in operating cash.
Guidance, Outlook, and Risks
Subsequent Event (Capital Injection): In July 2011, shortly after the fiscal year-end, the Company entered into an asset purchase agreement with Intuitive Surgical Operations, Inc., receiving $2.5 million for the sale of certain intellectual property. This capital is intended to retire outstanding long-term debt and fund operations. A gain of approximately $2.3 million is expected to be recognized in the quarter ending September 30, 2011.
Outlook: Management expects operating losses to continue through fiscal 2012 until sales increase to breakeven levels. Future growth is anticipated from Lenslock endoscopes, micro-precision optical elements, and next-generation handheld stereoendoscopes.
Key Risks:
- Liquidity and Debt: As of June 30, 2011, the Company had significant current liabilities ($2.3M) against minimal cash ($19.5K). The $600,000 principal plus accrued interest on Senior Secured Convertible Notes was due September 30, 2011.
- Customer Concentration: The top three customers accounted for 63% of revenues in 2011. Loss of any major customer could materially impact results.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and inventory valuation.
- Stock Liquidity: Common stock trades on the OTCQB market and is subject to "penny stock" rules, which may limit liquidity.
Investor Verification Checklist
- Debt Resolution: Verify the status of the $780,833 Senior Secured Convertible Notes due September 30, 2011, and confirm whether the $2.5 million proceeds from Intuitive Surgical were utilized to retire this debt.
- Intellectual Property License: Confirm the terms of the royalty-free license granted back by Intuitive Surgical to ensure the Company retains the right to manufacture its core products outside of medical robotics.
- Deferred Compensation Settlement: Verify the issuance of 245,326 shares of common stock to settle $674,645 in accrued officer salaries and director fees, and assess the resulting dilution.
- Customer Retention: Monitor revenue concentration risks given that the top three customers represent nearly two-thirds of total revenue.
- Internal Control Remediation: Review subsequent filings for updates on the remediation of material weaknesses in segregation of duties and inventory valuation.